LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS
Umeyor, C., Ezechukwu, I., Okafor, C., Ibe, M., Okeke, T., Nebolisa, N., Uronnachi, E., Attama, A. (2022). LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS. EKB Journal Management System, 45(2), 533-564. doi: 10.21608/bfsa.2022.271487
Chukwuebuka Emmanuel Umeyor; Ifeyinwa Ezechukwu; Chiamaka Okafor; Marksaviour Ibe; Tochukwu Okeke; Ngozi Nebolisa; Emmanuel Uronnachi; Anthony Attama. "LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS". EKB Journal Management System, 45, 2, 2022, 533-564. doi: 10.21608/bfsa.2022.271487
Umeyor, C., Ezechukwu, I., Okafor, C., Ibe, M., Okeke, T., Nebolisa, N., Uronnachi, E., Attama, A. (2022). 'LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS', EKB Journal Management System, 45(2), pp. 533-564. doi: 10.21608/bfsa.2022.271487
Umeyor, C., Ezechukwu, I., Okafor, C., Ibe, M., Okeke, T., Nebolisa, N., Uronnachi, E., Attama, A. LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS. EKB Journal Management System, 2022; 45(2): 533-564. doi: 10.21608/bfsa.2022.271487

LIPID NANOEMULSION-BASED LIQUISOLID COMPACT TABLETS FOR ORAL DELIVERY OF CLOTRIMAZOLE: FABRICATION STRATEGIES, CHARACTERIZATIONS, ANTIMYCOTIC AND TOXICOLOGICAL EVALUATIONS

Bulletin of Pharmaceutical Sciences Assiut University
Volume 45, Issue 2, December 2022, Page 533-564  XML PDF (2.41 MB)
Document Type: Original Article
DOI: 10.21608/bfsa.2022.271487
View on SCiNiTO View on SCiNiTO
Authors
Chukwuebuka Emmanuel Umeyor email 1; Ifeyinwa Ezechukwu1; Chiamaka Okafor1; Marksaviour Ibe1; Tochukwu Okeke1; Ngozi Nebolisaorcid 1; Emmanuel Uronnachi1; Anthony Attama2
1Nanomedicines and Drug Delivery Research Group, Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmaceutical Sciences, Nnamdi Azikiwe University, Awka, 422001, Anambra State, Nigeria
2Drug Delivery and Nanomedicine Research Group, Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, 410001, Enugu State, Nigeria
Abstract
This work aims to fabricate liquisolid compact tablets incorporating clotrimazole (CLOT)-loaded lipid nanoemulsions (LNE) for oral treatment of systemic fungal infections. Nanoemulsion was characterized for droplet size, rendered into free-flowing granules and compressed into liquisolid compact tablets, and evaluated using pharmacopoeial and non-pharmacopoeial methods. In-vitro and in vivo antifungal, stability and toxicological tests of the tablets were evaluated. LNE was nanosized (66.7 ± 5.7 – 121.6 ± 3.2 nm). Liquisolid tablets were stable, non-toxic, had uniform weight (341.4 ± 1.2 – 346.7 ± 0.8 mg), drug content uniformity (85.2 ± 0.1 – 99.8 ± 0.2 %), and had excellent disintegration (2.96 ± 0.8 – 5.88 ± 1.3 min), and controlled release property. In-vitro and in vivo antifungal evaluations revealed improved antimycotic activity of CLOT. The results highlight that CLOT-LNE liquisolid compact tablets is a promising carrier system with improved oral utility for the treatment of systemic fungal infections.
Keywords
Clotrimazole; Lipid nanoemulsion; Liquisolid; Systemic mycoses; Candida albicans; Oral delivery
Statistics
Article View: 175
PDF Download: 231